KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xperi (XPER) Minority Interest (2021 - 2024)

Xperi has reported Minority Interest over the past 4 years, most recently at -$21.6 million for Q3 2024.

  • Quarterly results put Minority Interest at -$21.6 million for Q3 2024, down 29.05% from a year ago — trailing twelve months through Sep 2024 was -$21.6 million (down 29.05% YoY), and the annual figure for FY2023 was -$17.1 million, down 18.47%.
  • Minority Interest for Q3 2024 was -$21.6 million at Xperi, down from -$18.7 million in the prior quarter.
  • Over the last five years, Minority Interest for XPER hit a ceiling of -$9.2 million in Q4 2021 and a floor of -$21.6 million in Q3 2024.
  • Median Minority Interest over the past 4 years was -$16.5 million (2023), compared with a mean of -$16.0 million.
  • Biggest five-year swings in Minority Interest: plummeted 56.78% in 2022 and later fell 13.21% in 2024.
  • Xperi's Minority Interest stood at -$9.2 million in 2021, then plummeted by 56.78% to -$14.4 million in 2022, then decreased by 18.47% to -$17.1 million in 2023, then dropped by 26.26% to -$21.6 million in 2024.
  • The last three reported values for Minority Interest were -$21.6 million (Q3 2024), -$18.7 million (Q2 2024), and -$17.4 million (Q1 2024) per Business Quant data.